<DOC>
	<DOCNO>NCT01879228</DOCNO>
	<brief_summary>In recent year , diabetes emerge one significant co-diseases many Cystic Fibrosis ( CF ) patient develop . Type 1 Type 2 diabetes result either body make enough insulin body respond correctly insulin . Insulin hormone make cell pancreas help carry glucose ( sugar ) food eat cell body energy . While cystic fibrosis relate diabetes ( CFRD ) many feature similar Type 1 Type 2 diabetes , different ; therefore , treatment care CFRD . The purpose research study examine understand various mechanism contribute CFRD gain well understanding potential mean treat CFRD . The primary objective determine effectiveness chronic incretin-based therapy vs. placebo insulin secretion CF patient indeterminate glucose tolerance , impair glucose tolerance , CFRD .</brief_summary>
	<brief_title>Effect Chronic Incretin-based Therapy Cystic Fibrosis</brief_title>
	<detailed_description>Insufficient incretin action associate T2D . To study possible link insufficient incretin action impair insulin secretion CFRD T2D , present study determine whether early intervention incretin-based therapy use DPP-4 inhibitor sitagliptin ( Januvia® ) raise endogenous level incretin hormone -- i.e. -- glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotrophic polypeptide ( GIP ) 6-month period improve insulin secretion CF patient indeterminate glucose tolerance , impair glucose tolerance early CFRD .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 ) Confirmed diagnosis CF , define positive sweat test CFTR mutation analysis accord CFF diagnostic criterion , 2 ) age ≥ 18y date consent , 3 ) pancreatic insufficiency , 4 ) recent OGTT consistent IndeterminateGT , IGT , CFRD w/o fast hyperglycemia , establish diagnosis CFRD without fast hyperglycemia , 5 ) female subject , negative urine pregnancy test enrollment . 1 ) Established diagnosis nonCF diabetes ( i.e . T1D ) CFRD fast hyperglycemia , ( fast glucose &gt; 126 mg/dL ) 2 ) history clinically symptomatic pancreatitis within last year , 3 ) prior lung liver transplant , 4 ) severe CF liver disease , define portal hypertension , 5 ) fundoplicationrelated dump syndrome , 6 ) medical comorbidities CFrelated unstable per investigator opinion ( i.e . history bleed disorder , immunodeficiency ) , 7 ) acute illness change therapy ( include antibiotic ) within 6 week prior enrollment , 8 ) treatment oral intravenous corticosteroid within 6 week enrollment , 9 ) hemoglobin &lt; 10g/dL , within 90 day Visit 1 Screening , 10 ) abnormal renal function , within 90 day Visit 1 Screening ; define Creatinine clearance &lt; 50 mL/min ( base CockcroftGault formula ) potassium &gt; 5.5mEq/L nonhemolyzed specimen , 11 ) history anaphylaxis , angioedema StevensJohnson syndrome , 12 ) Inability perform study specific procedure ( MMTT , GPA ) , 13 ) Subjects , study team opinion , may noncompliant study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Pancreatic Insufficiency</keyword>
</DOC>